BR9606969A - Associação medicamentosa de um ou vários ácidos nucléico inibindo ao menos parcialmente as vias de sinalização celulares oncogênicas e de um agente terapêutico anticanceroso e associação medicamentosa de um ou vários genes supressores de tumores e de um taxóide - Google Patents

Associação medicamentosa de um ou vários ácidos nucléico inibindo ao menos parcialmente as vias de sinalização celulares oncogênicas e de um agente terapêutico anticanceroso e associação medicamentosa de um ou vários genes supressores de tumores e de um taxóide

Info

Publication number
BR9606969A
BR9606969A BR9606969A BR9606969A BR9606969A BR 9606969 A BR9606969 A BR 9606969A BR 9606969 A BR9606969 A BR 9606969A BR 9606969 A BR9606969 A BR 9606969A BR 9606969 A BR9606969 A BR 9606969A
Authority
BR
Brazil
Prior art keywords
drug association
nucleic acids
taxoid
partially
therapeutic agent
Prior art date
Application number
BR9606969A
Other languages
English (en)
Portuguese (pt)
Inventor
Bruno Tocque
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of BR9606969A publication Critical patent/BR9606969A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR9606969A 1995-01-17 1996-01-12 Associação medicamentosa de um ou vários ácidos nucléico inibindo ao menos parcialmente as vias de sinalização celulares oncogênicas e de um agente terapêutico anticanceroso e associação medicamentosa de um ou vários genes supressores de tumores e de um taxóide BR9606969A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9500436A FR2729295A1 (fr) 1995-01-17 1995-01-17 Traitement therapeutique combine des pathologies hyperproliferatives
PCT/FR1996/000056 WO1996022101A1 (fr) 1995-01-17 1996-01-12 Traitement therapeutique combine des pathologies hyperproliferatives

Publications (1)

Publication Number Publication Date
BR9606969A true BR9606969A (pt) 1997-11-04

Family

ID=9475169

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9606969A BR9606969A (pt) 1995-01-17 1996-01-12 Associação medicamentosa de um ou vários ácidos nucléico inibindo ao menos parcialmente as vias de sinalização celulares oncogênicas e de um agente terapêutico anticanceroso e associação medicamentosa de um ou vários genes supressores de tumores e de um taxóide

Country Status (21)

Country Link
US (3) US6262032B1 (fr)
EP (1) EP0800399B1 (fr)
JP (3) JP4580469B2 (fr)
KR (1) KR100385266B1 (fr)
AT (1) ATE222109T1 (fr)
AU (1) AU716364B2 (fr)
BR (1) BR9606969A (fr)
CA (1) CA2209771C (fr)
CZ (1) CZ298710B6 (fr)
DE (1) DE69622989T2 (fr)
DK (1) DK0800399T3 (fr)
ES (1) ES2180729T3 (fr)
FI (1) FI119911B (fr)
FR (1) FR2729295A1 (fr)
HU (1) HU229484B1 (fr)
MX (1) MX9704490A (fr)
NO (1) NO325418B1 (fr)
PT (1) PT800399E (fr)
SI (1) SI0800399T1 (fr)
SK (1) SK283989B6 (fr)
WO (1) WO1996022101A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044396A1 (en) * 1998-04-21 2003-03-06 Elia James P. Methods for treating diseases and increasing longevity
FR2729295A1 (fr) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
US7087582B1 (en) 1995-09-26 2006-08-08 Regents Of The University Of Michigan Combination for site-specifically transforming cells in vivo comprising a double-balloon catheter and nucleic acid comprising a gene encoding P21
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US20030060434A1 (en) * 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US20030064949A1 (en) * 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
AU2002236765A1 (en) 2001-01-16 2002-07-30 Glaxo Group Limited Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
CN1816564B (zh) * 2003-06-30 2010-11-24 洛桑大学 能选择性杀伤癌细胞的RasGAP衍生肽
JPWO2005061007A1 (ja) * 2003-12-24 2007-07-12 学校法人 聖マリアンナ医科大学 癌の抑制方法
WO2005061001A1 (fr) * 2003-12-24 2005-07-07 Locomogene, Inc. Methode d'elimination du cancer
GB0406415D0 (en) * 2004-03-22 2004-04-21 Inst Of Cancer Res The Materials and methods for treatment of cancer
US8124598B2 (en) * 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
US20100111874A1 (en) * 2007-03-19 2010-05-06 University Of Medicine And Dentistry Of New Jresey Method of cancer detection and treatment
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2634833B2 (ja) * 1986-03-28 1997-07-30 ボード オブ トラステイーズ オブ ユニヴアーシテイ オブ イリノイ ヒト細胞における複数薬剤耐性に関連するｄｎａ配列を含むクローンの組成および方法
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
CA2136091A1 (fr) * 1992-05-20 1993-11-25 Daniel S. Martin Combinaisons medicamenteuses chimiotherapeutiques
DE69329336D1 (de) * 1992-05-28 2000-10-05 Xenova Ltd Acridin carboxamide zur behandlung von krebs
FR2694296B1 (fr) * 1992-07-30 1994-09-02 Rhone Poulenc Rorer Sa Peptides inhibant l'activité des protéines ras, préparation et utilisation.
US6348352B1 (en) * 1992-09-18 2002-02-19 Canji, Inc. Methods for selectively transducing pathologic mammalian cells using a tumor suppressor gene
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
TW442569B (en) 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
FR2729295A1 (fr) * 1995-01-17 1996-07-19 Rhone Poulenc Rorer Sa Traitement therapeutique combine des pathologies hyperproliferatives
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6054467A (en) 1996-07-05 2000-04-25 Sidney Kimmel Cancer Center Down-regulation of DNA repair to enhance sensitivity to P53-mediated apoptosis

Also Published As

Publication number Publication date
ES2180729T3 (es) 2003-02-16
CA2209771C (fr) 2012-01-03
US6262032B1 (en) 2001-07-17
DE69622989T2 (de) 2002-12-05
FR2729295B1 (fr) 1997-02-28
JPH10512559A (ja) 1998-12-02
SK283989B6 (sk) 2004-07-07
US7884082B2 (en) 2011-02-08
US20040127437A1 (en) 2004-07-01
AU4542996A (en) 1996-08-07
NO325418B1 (no) 2008-04-21
HUP9802423A2 (hu) 1999-02-01
WO1996022101A1 (fr) 1996-07-25
DK0800399T3 (da) 2002-12-02
NO973197D0 (no) 1997-07-09
KR100385266B1 (ko) 2005-09-07
CZ298710B6 (cs) 2008-01-02
JP4580469B2 (ja) 2010-11-10
CZ226297A3 (en) 1997-10-15
ATE222109T1 (de) 2002-08-15
EP0800399A1 (fr) 1997-10-15
NO973197L (no) 1997-07-09
FI973023A (fi) 1997-07-16
JP2012036201A (ja) 2012-02-23
HU229484B1 (en) 2014-01-28
DE69622989D1 (de) 2002-09-19
SI0800399T1 (en) 2002-12-31
SK95797A3 (en) 1997-12-10
FI973023A0 (fi) 1997-07-16
PT800399E (pt) 2002-12-31
FR2729295A1 (fr) 1996-07-19
CA2209771A1 (fr) 1996-07-25
EP0800399B1 (fr) 2002-08-14
KR19980701449A (ko) 1998-05-15
US20010021395A1 (en) 2001-09-13
AU716364B2 (en) 2000-02-24
US20050209177A9 (en) 2005-09-22
JP5031921B2 (ja) 2012-09-26
JP2008133291A (ja) 2008-06-12
HUP9802423A3 (en) 2000-11-28
FI119911B (fi) 2009-05-15
MX9704490A (es) 1997-10-31

Similar Documents

Publication Publication Date Title
BR9606969A (pt) Associação medicamentosa de um ou vários ácidos nucléico inibindo ao menos parcialmente as vias de sinalização celulares oncogênicas e de um agente terapêutico anticanceroso e associação medicamentosa de um ou vários genes supressores de tumores e de um taxóide
ES2077530B1 (es) Procedimiento para la preparacion de productos farmaceuticos para curar enfermedades tumorales.
ATE307608T1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
EG20380A (en) Enhanced skin penetration system for improved topical delivery of drugs
BR0109704A (pt) Método de tratamento usando conjugados de imunógeno ligando
BR0117063A (pt) Uso de ciclopamina no tratamento de carcinoma de células basais e outros tumores
BR9810465A (pt) Inibidores da farnesiltransferase de proteìnas
GT199900151A (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial.
CY1105788T1 (el) Χρηση του taci σαν παραγοντα καταπολεμησης ογκων
MY101570A (en) Novel pharmaceutical compositions for topical application with systemic action
IL121272A (en) Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
WO2000061141A3 (fr) Methodes et compositions ameliorant la diffusion d'agents therapeutiques a l'interieur de tissus
EA200201068A1 (ru) Способ и композиция для лечения рака введением химиотерапевтических средств, вызывающих апоптоз
IL103065A0 (en) Protein for inhibiting platelet aggregation,processes for the preparation thereof and a pharmaceutical composition containing the same
ATE344664T1 (de) Verbesserte methode zur eradikation von helicobacter pylori
DE69626544T2 (de) Arzneistoffe
WO2005013802A3 (fr) Peptide en trefle tff3 utilise comme cible dans la therapie anticancereuse
WO2002076393A3 (fr) Agents antiangionenes, antitumoraux, et chimiopreventifs
DE3163920D1 (en) Pharmaceutical preparations comprising polyprenyl compounds, especially as anti-cancer agents, and pharmaceutical compositions for the prevention and treatment of cancer and skin diseases
HUP9901935A2 (hu) Gyógyszerek és terápiás szerek és más glikozaminoglikánok (GAG) dózisainak célbajuttatására alkalmas dóziskészlet
IL156144A0 (en) Novel therapeutic use of a thienylcyclohexylamine derivative
FR2759586B1 (fr) Medicament de type anticancereux comportant au moins a titre de principe actif du 1-alpha hydroxycalciferol ou alfacalcidol
MX9804576A (es) Composiciones que contienen bismuto, para la prevencion y tratamiento de trastornos gastrointestinales.
UA30332A (uk) Спосіб лікування псоріазу
ITBO990111A1 (it) Prodotto , metodo ed uso di poliacrilammide come veicolo per sostanzefarmacologiche .

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
TC Change of name
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 37, INDEFIRO O PRESENTE PEDIDO COM BASE NO ARTIGO 10 (VIII) DA LPI VIGENTE.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/70 (2006.01), A61K 33/24 (2006.0